Remepy
Hybrid Drug therapies are developed to combine pharmaceutical programs with software-based treatment components for clinical use.
Overview
Remepy is building a Hybrid Drug™ pipeline that pairs drug development with software-enabled therapeutic components. Its lead program, Hybridopa™, is being advanced into Phase III, with the company positioning the platform for use through pharmaceutical partnerships. The company targets pharmaceutical partners and healthcare markets seeking differentiated therapeutic programs that blend conventional drugs with digital treatment layers. Remepy raised a $36 million Series A in August 2026 to expand its pipeline and support the next clinical stage for Hybridopa™.
Funding History
Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Par
Frequently Asked Questions
- How much funding does AI Funding track for Remepy?
- AI Funding tracks $36M for Remepy across 1 funding round in this database.
- What does Remepy do?
- Remepy is building a Hybrid Drug™ pipeline that pairs drug development with software-enabled therapeutic components. Its lead program, Hybridopa™, is being advanced into Phase III, with the company positioning the platform for use through pharmaceutical partnerships. The company targets pharmaceutical partners and healthcare markets seeking differentiated therapeutic programs that blend conventional drugs with digital treatment layers. Remepy raised a $36 million Series A in August 2026 to expand its pipeline and support the next clinical stage for Hybridopa™.
- Where is Remepy headquartered?
- Remepy is headquartered in Tel Aviv, Israel.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.